Evaluation of N-desmethylclozapine as a potential antipsychotic - Preclinical studies

Neuropsychopharmacology

Volumn 32, Issue 7, 2007, Pages 1540-1549

  Natesan, Sridhar ^a   Reckless, Greg E ^a   Barlow, Karen B L ^a   Nobrega, José N ^a,b,c   Kapur, Shitij ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic animal models; Clozapine; D 2 5 HT2 receptor occupancy; D2 receptors; N desmethylclozapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MOLECULAR MARKER; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NORCLOZAPINE; PROLACTIN; PROTEIN FOS; RACLOPRIDE; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HYPERPROLACTINEMIA; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; CATALEPSY; CLOZAPINE; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; HALOPERIDOL; MALE; PIPERAZINES; PROLACTIN; PROTO-ONCOGENE PROTEINS C-FOS; PSYCHOTIC DISORDERS; QUINOLONES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 34250358686     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301279     Document Type: Article

References (62)

1. Ahlenius S, Hillegaart V (1986). Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 24: 1409-1415.
2. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
3. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993). Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9: 117-124.
4. 1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci 18: 512-524.
5. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473.
6. Bolden C, Cusack B, Richelson E (1991). Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 192: 205-206.
7. Bondesson U, Lindstrom LH (1988). Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berlin) 95: 472-475.
8. Buchanan RW (1995). Clozapine: efficacy and safety. Schizophr Bull 21: 579-591.
9. 3 partial agonist. J Pharmacol Exp Ther 315: 1278-1287.
10. Bymaster FP, Felder C, Ahmed S, McKinzie D (2002). Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1: 163-181.
11. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003). Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1125-1143.
12. Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO et al (1999). Potential role of muscarinic receptors in schizophrenia. Life Sci 64: 527-534.
13. Chang WH, Lin SK, Lane HY, Wei FC, Hu WH, Lam YW et al (1998). Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 22: 723-739.
14. Dain JG, Nicoletti J, Ballard F (1997). Biotransformation of clozapine in humans. Drug Metab Dispos 25: 603-609.
15. 1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berlin) 178: 451-460.
16. Dettling M, Sachse C, Brockmoller J, Schley J, Muller-Oerlinghausen B, Pickersgill I et al (2000). Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berlin) 152: 80-86.
17. Deutch AY, Lee MC, Iadarola MJ (1992). Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neuroscience 3: 332-341.
18. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L (1997). The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44: 439-446.
19. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
20. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76.
21. Finney DJ (1971). Probit Analysis. Cambridge University Press: London.
22. Floresco SB, Geyer MA, Gold LH, Grace AA (2005). Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull 31: 888-894.
23. Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ et al (2003). Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 23: 87-91.
24. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383-390.
25. Herrera DG, Robertson HA (1996). Activation of c-fos in the brain. Prog Neurobiol 50: 83-107.
26. Hertel P, Fagerquist MV, Svensson TH (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286: 105-107.
27. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
28. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002). The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302: 1129-1134.
29. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
30. 1C receptor antagonists. Eur J Pharmacol 245: 179-182.
31. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (2005). N- desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30: 1986-1995.
32. 2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 27: 691-698.
33. Mauri M, Volonteri LS, Fiorentini A, Invernizzi G, Nerini T, Baldi M et al (2004). Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 66: 197-198.
34. Mauri MC, Volonteri LS, Dell'Osso B, Regispani F, Papa P, Baldi M et al (2003). Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23: 660-664.
35. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82-91.
36. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390-392.
37. McQuade RD, Duffy RA, Coffin VL, Barnett A (1992). In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur J Pharmacol 251: 29-34.
38. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31: 1854-1863.
39. Olesen OV, Linnet K (2001). Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 41: 823-832.
40. 1 agonist C-APB. Pharmacol Biochem Behav 63: 237-243.
41. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic press: New York.
42. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231-235.
43. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995). Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272: 984-990.
44. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690.
45. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058-1066.
46. 1A receptor activation. Eur J Pharmacol 338: R3-R5.
47. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH et al (1999). Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 290: 901-907.
48. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M et al (2000). Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 33: 213-217.
49. 2 receptor occupancy. Neuropsychopharmacology 12: 57-64.
50. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004). Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berlin) 171: 306-321.
51. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674-13679.
52. Takamori K, Hirota S, Chaki S, Tanaka M (2003). Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci 73: 1721-1728.
53. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP et al (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159: 255-262.
54. Wadenberg MG, Browning JL, Young KA, Hicks PB (2001a). Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68: 363-370.
55. 2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47: 509-513.
56. 2 receptor antagonist raclopride in rats. J Neural Transm 107: 1229-1238.
57. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berlin) 150: 422-429.
58. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001b). Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25: 633-641.
59. Weigmann H, Hartter S, Fischer V, Dahmen N, Hiemke C (1999). Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharmacol 9: 253-256.
60. 1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berlin) 177: 207-216.
61. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472.
62. Young CD, Meltzer HY, Deutch AY (1998). Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacology 19: 99-103.